Skip to Content
Merck
  • Two weeks of buspirone protects against posthypoxic ventilatory pauses in the C57BL/6J mouse strain.

Two weeks of buspirone protects against posthypoxic ventilatory pauses in the C57BL/6J mouse strain.

Respiratory physiology & neurobiology (2012-05-19)
M W Moore, S Chai, C B Gillombardo, A Carlo, L M Donovan, N Netzer, K P Strohl
ABSTRACT

The purpose was to determine if 2 weeks of buspirone suppressed post-hypoxic breathing instability and pauses in the C57BL/6J (B6) mouse. Study groups were vehicle (saline, n=8), low-dose (1.5 mg/kg, n=8), and high-dose buspirone (5.0 mg/kg, n=8). Frequency, measured by plethysmography, was the major metric, and a pause defined by breathing cessation >2.5 times the average frequency. Mice were tested after 16 days of ip injections of vehicle or drug. On day 17, 4 mice in each group were tested after buspirone and the 5-HT(1A) receptor antagonist, 4-iodo-N-{2-[4-(methoxyphenyl)-1-piperazinyl] ethyl}-N-2-pyridinyl-benzamide (p-MPPI, 5 mg/kg). A post-hypoxic pause was present in 6/8 animals given vehicle and 1/16 animals given buspirone at either dose, but always present (8/8) with p-MPPI, regardless of buspirone dose. Post-hypoxic frequency decline was blunted by buspirone (-10% vehicle vs. -5% at both doses) and restored by p-MPPI; ventilatory stability as described by the coefficient of variation which was reduced by buspirone (p<0.04) was increased by p-MPPI (0.01). In conclusion, buspirone administration after 2 weeks acts through the 5-HT(1A) receptor to reduce post-hypoxic ventilatory instability in the B6 strain.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Buspirone hydrochloride
Buspirone for system suitability, European Pharmacopoeia (EP) Reference Standard